Bal Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bal Pharma Limited reported FY2026 standalone revenue of Rs. 31,079.70 lakhs, up 2.74% from Rs. 30,249.64 lakhs in FY2025. However, net profit declined 13.4% to Rs. 675.12 lakhs from Rs. 779.95 lakhs in the prior year. EPS fell to Rs. 4.51 from Rs. 4.89. Consolidated results showed similar trends with revenue of Rs. 31,166.13 lakhs and net profit of Rs. 632 lakhs. The company recommended a dividend of Rs. 1.20 per equity share (12%). The Board also approved 500,000 stock options for employees and a preferential issue of 10 million warrants to promoters. Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated financials.
The decline in net profit despite modest revenue growth signals margin compression, which could concern investors. The clean audit opinion and positive operating cash flow of Rs. 3,044 lakhs provide some comfort, but the profit contraction and preferential warrant issuance to promoters warrant close monitoring.